Galera Therapeutics Inc. (NASDAQ:GRTX) saw a downside of -2.76% to close Tuesday at $2.11 after subtracting -$0.06 on the day. The 5-day average trading volume is 1,871,940 shares of the company’s common stock. It has gained $2.39 in the past week and touched a new high 2 times within the past 5 days. An average of 1,294,570 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 884,772.
GRTX’s 1-month performance is -27.99% or -$0.82 on its low of $1.96 reached on 08/08/23. The company’s shares have touched a 52-week low of $1.16 and high of $3.59, with the stock’s rally to the 52-week high happening on 06/13/23. YTD, GRTX has achieved 41.61% or $0.62 and has reached a new high 15 times. However, the current price is down -41.23% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
GRTX stock has a beta of 1.75.
Galera Therapeutics Inc.’s quick ratio for the period ended March 30 was 4.10, with the current ratio over the same period at 4.10. The firm’s gross profit as reported stood at $11.57 million against revenue of $51.23 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Galera Therapeutics Inc.’s cash and short-term investments amounted to $22.06 million against total debt of $143.86 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 12.82% to -$17.71 million, while revenue of -$16.19 million was 8.58% off the previous quarter. Analysts expected GRTX to announce -$0.38 per share in earnings in its latest quarter, but it posted -$0.5, representing a -31.60% surprise. EBITDA for the quarter stood at more than -$13.86 million. GRTX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 157.33 million, with total debt at $143.86 million. Shareholders hold equity totaling $42.91 million.
Let’s look briefly at Galera Therapeutics Inc. (GRTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 30.50% to suggest the stock is trending Neutral, with historical volatility in this time period at 97.69%.
The stock’s 5-day moving average is $2.18, reflecting a -7.05% or -$0.16 change from its current price. GRTX is currently trading -26.48% above its 20-day SMA, -5.38% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -28.47% and SMA200 by+29.45%.
Stochastic %K and %D was 14.26% and 13.36% and the average true range (ATR) pointed at 0.21. The RSI (14) points at 33.25%, while the 14-day stochastic is at 15.96% with the period’s ATR at 0.20. The stock’s 9-day MACD Oscillator is pointing at -0.12 and -0.23 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Galera Therapeutics Inc. (NASDAQ: GRTX), BTIG Research downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for GRTX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate GRTX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is GRTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $12.00, with their median price target at $6.50. Looking at these predictions, the average price target given by analysts is for Galera Therapeutics Inc. (GRTX) stock is $7.75.
